Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in advanced thymic epithelial tumors
NCT02607631Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Nov 2015
- Primary completion
- Feb 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in thymic epithelial tumor (TET), sponsored by Samsung Medical Center. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
thymic epithelial tumor (TET)
Beyond the preview
Go deeper on NCT02607631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607631.